Department of Onco-Hematology and Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS; and Department of Biomedicine and Prevention, University of Rome "Tor Vergata", Rome, Italy.
Department of Onco-Hematology and Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Semin Oncol Nurs. 2023 Oct;39(5):151478. doi: 10.1016/j.soncn.2023.151478. Epub 2023 Aug 4.
This systematic review aims to describe an overview of the overall care, patient and parent education, staff training, and management of complications from a nursing perspective of pediatric patients undergoing chimeric antigen receptor T (CAR-T) cell infusion in order to provide an updated summary of the approach to the management of these patients. CAR-T cellular therapy represents an innovation within pediatric hematology and oncology used to treat relapse and refractory leukemias, solid tumors, and lymphomas when standard therapy has not worked. However, this type of therapy could lead to the onset of some clinical complications that must be managed appropriately and promptly. Although their use is constantly increasing, the knowledge and resources in the literature are still limited.
The review was conducted from January 2022 to July 2022 in PubMed, CINAHL, Scopus, and Cochrane and produced 502 articles. Based on the selection criteria and after removing duplicate articles, 26 articles were included in the study.
From these analyzed articles, it was possible to have an overview regarding the management, patient and parent education, staff training, and management of complications from a nursing perspective of pediatric patients undergoing CAR-T cell infusion.
The management of hematology-oncology patients undergoing CAR-T cell therapy from a nursing perspective is not simple. We hope this review can be used as a tool to guide nursing staff. In this regard, we have developed a summary table with the actions to be taken in the case of assisting a pediatric patient being treated with CAR-T.
本系统评价旨在从护理角度描述儿科患者接受嵌合抗原受体 T（CAR-T）细胞输注的整体护理、患者和家长教育、人员培训以及并发症管理的概述，以便为这些患者的管理方法提供最新总结。CAR-T 细胞疗法是儿科血液学和肿瘤学领域的一项创新，用于治疗标准治疗无效的复发和难治性白血病、实体瘤和淋巴瘤。然而，这种治疗方法可能会导致一些临床并发症的发生，这些并发症必须得到适当和及时的处理。尽管它们的使用不断增加，但文献中的知识和资源仍然有限。
本综述于 2022 年 1 月至 7 月在 PubMed、CINAHL、Scopus 和 Cochrane 中进行，共产生了 502 篇文章。基于选择标准并在去除重复文章后，有 26 篇文章被纳入研究。
从这些分析的文章中，可以从护理角度对儿科患者接受 CAR-T 细胞输注的管理、患者和家长教育、人员培训以及并发症管理有一个概述。
从护理角度管理接受 CAR-T 细胞治疗的血液肿瘤学患者并不简单。我们希望本综述可以用作指导护理人员的工具。在这方面，我们已经制定了一个总结表，列出了在协助接受 CAR-T 治疗的儿科患者时应采取的行动。
